220 related articles for article (PubMed ID: 34922515)
1. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
3. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.
Padilla-Galo A; Moya Carmona I; Ausín P; Carazo Fernández L; García-Moguel I; Velasco-Garrido JL; Andújar-Espinosa R; Casas-Maldonado F; Martínez-Moragón E; Martínez Rivera C; Vera Solsona E; Sánchez-Toril López F; Trisán Alonso A; Blanco Aparicio M; Valverde-Monge M; Valencia Azcona B; Palop Cervera M; Nuevo J; Sánchez Tena J; Resler G; Luzón E; Levy Naon A
Respir Res; 2023 Sep; 24(1):235. PubMed ID: 37770889
[TBL] [Abstract][Full Text] [Related]
4. Real-life experience with benralizumab during 6 months.
Padilla-Galo A; Levy-Abitbol R; Olveira C; Valencia Azcona B; Pérez Morales M; Rivas-Ruiz F; Tortajada-Goitia B; Moya-Carmona I; Levy-Naon A
BMC Pulm Med; 2020 Jun; 20(1):184. PubMed ID: 32600318
[TBL] [Abstract][Full Text] [Related]
5. Real-life cost-effectiveness of benralizumab in patients with severe asthma.
Padilla-Galo A; García-Ruiz AJ; Levy Abitbol RC; Olveira C; Rivas-Ruiz F; García-Agua Soler N; Pérez Morales M; Valencia Azcona B; Tortajada-Goitia B; Moya-Carmona I; Levy-Naon A
Respir Res; 2021 May; 22(1):163. PubMed ID: 34044819
[TBL] [Abstract][Full Text] [Related]
6. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
[TBL] [Abstract][Full Text] [Related]
7. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
[No Abstract] [Full Text] [Related]
8. Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2.
Carstens D; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Chung Y
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2150-2161.e4. PubMed ID: 37146880
[TBL] [Abstract][Full Text] [Related]
9. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis R; Harrison TW; Chanez P; Menzella F; Philteos G; Cosio BG; Lugogo NL; de Luiz G; Burden A; Adlington T; Keeling N; Kwiatek J; Garcia Gil E;
J Allergy Clin Immunol Pract; 2023 Jun; 11(6):1759-1770.e7. PubMed ID: 36948488
[TBL] [Abstract][Full Text] [Related]
10. Exploring the risk of infection events in patients with asthma receiving
Giossi R; Pani A; Schroeder J; Scaglione F
Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
[TBL] [Abstract][Full Text] [Related]
12. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
Kayser MZ; Suhling H; Fuge J; Hinze CA; Drick N; Kneidinger N; Behr J; Taube C; Welte T; Haasler I; Milger K
BMC Pulm Med; 2024 Mar; 24(1):149. PubMed ID: 38515071
[TBL] [Abstract][Full Text] [Related]
13. Exacerbations, treatment patterns, utilization, and costs before and after initiating of benralizumab for the treatment of severe eosinophilic asthma.
Smith JL; Chung Y; Barron J; Barlows T; Nepal B; Carstens D
J Asthma; 2024 Jun; 61(6):520-531. PubMed ID: 38054593
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
Desaintjean C; Ahmad K; Traclet J; Gerfaud-Valentin M; Durel CA; Glerant JC; Hot A; Lestelle F; Mainbourg S; Nasser M; Seve P; Turquier S; Devouassoux G; Cottin V
Front Med (Lausanne); 2024; 11():1341310. PubMed ID: 38585151
[TBL] [Abstract][Full Text] [Related]
15. Benralizumab in severe eosinophilic asthma: A real-world, single-center, observational study from Mexico.
Luis MRJ; Del Carmen LEE; Arroyo ARM; Jorge SH; Mauricio CV; Monserrat EP; Del Carmen CSM
Allergol Immunopathol (Madr); 2023; 51(6):8-15. PubMed ID: 37937490
[TBL] [Abstract][Full Text] [Related]
16. Effect of Benralizumab on Mucus Plugs in Severe Eosinophilic Asthma.
Sakai N; Koya T; Murai Y; Tsubokawa F; Tanaka K; Naramoto S; Aoki A; Shima K; Kimura Y; Watanabe S; Hasegawa T; Kikuchi T
Int Arch Allergy Immunol; 2023; 184(8):783-791. PubMed ID: 37231966
[TBL] [Abstract][Full Text] [Related]
17. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
Jackson DJ; Heaney LG; Humbert M; Kent BD; Shavit A; Hiljemark L; Olinger L; Cohen D; Menzies-Gow A; Korn S;
Lancet; 2024 Jan; 403(10423):271-281. PubMed ID: 38071986
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis.
Kearney CM; Sangani R; Shankar D; O'Connor GT; Law AC; Walkey AJ; Bosch NA
Ann Am Thorac Soc; 2024 Jun; 21(6):866-874. PubMed ID: 38241013
[No Abstract] [Full Text] [Related]
19. Update on new biologics for intractable eosinophilic asthma: impact of reslizumab.
Sahota J; Robinson DS
Drug Des Devel Ther; 2018; 12():1173-1181. PubMed ID: 29780238
[TBL] [Abstract][Full Text] [Related]
20. Severe Asthma or Chronic Obstructive Pulmonary Disease with Eosinophilic Inflammation? From Uncertainty to Remission under Anti IL-5R Therapy.
Oprescu B; Raduna O; Mihaicuta S; Frent S
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541113
[No Abstract] [Full Text] [Related]
[Next] [New Search]